HomeLNTH • NASDAQ
add
Lantheus Holdings Inc
Previous close
$58.75
Day range
$58.24 - $58.83
Year range
$47.27 - $111.29
Market cap
3.89B USD
Avg Volume
1.23M
P/E ratio
29.75
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 384.01M | 1.39% |
Operating expense | 178.75M | 64.93% |
Net income | 27.77M | -78.82% |
Net profit margin | 7.23 | -79.11% |
Earnings per share | 1.27 | -25.29% |
EBITDA | 64.02M | -57.55% |
Effective tax rate | 34.47% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 382.01M | -55.91% |
Total assets | 2.28B | 11.06% |
Total liabilities | 1.16B | 33.02% |
Total equity | 1.12B | — |
Shares outstanding | 66.31M | — |
Price to book | 3.48 | — |
Return on assets | 4.96% | — |
Return on capital | 6.19% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | 27.77M | -78.82% |
Cash from operations | 105.29M | -39.85% |
Cash from investing | -319.47M | -371.21% |
Cash from financing | -99.17M | -5,405.83% |
Net change in cash | -313.56M | -386.67% |
Free cash flow | 89.36M | 54.03% |
About
Lantheus, headquartered in Billerica, Massachusetts, is a company in the radiopharmaceuticals business. It has strategic partnerships with Bayer, Novartis, Regeneron as well as GE Healthcare and Siemens Healthineers.
Lantheus Holding, which became a NASDAQ company in 2015, is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB. Lantheus has offices in Massachusetts, New Jersey, Canada and Sweden.
Brian Markison has served as the company's CEO since March 1, 2024, following the retirement of Mary Anne Heino, who had led Lantheus for the preceding decade. Wikipedia
Founded
1956
Headquarters
Website
Employees
808
